You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameQuinethazone
Accession NumberDB01325
TypeSmall Molecule
GroupsApproved
DescriptionQuinethazone (INN, brand name Hydromox) is a thiazide diuretic used to treat hypertension. Common side effects include dizziness, dry mouth, nausea, and low potassium levels.
Structure
Thumb
Synonyms
Chinetazone
Chinethazonum
Hydromox
Quinetazona
Quinethazon
Quinethazonum
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AquamoxNot Available
HydromoxNot Available
IdrokinNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII455E0S048W
CAS number73-49-4
WeightAverage: 289.739
Monoisotopic: 289.028789662
Chemical FormulaC10H12ClN3O3S
InChI KeyInChIKey=AGMMTXLNIQSRCG-UHFFFAOYSA-N
InChI
InChI=1S/C10H12ClN3O3S/c1-2-9-13-7-4-6(11)8(18(12,16)17)3-5(7)10(15)14-9/h3-4,9,13H,2H2,1H3,(H,14,15)(H2,12,16,17)
IUPAC Name
7-chloro-2-ethyl-4-oxo-1,2,3,4-tetrahydroquinazoline-6-sulfonamide
SMILES
CCC1NC(=O)C2=CC(=C(Cl)C=C2N1)S(N)(=O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as quinazolines. These are compounds containing a quinazoline moiety, which is made up of two fused six-member aromatic rings, a benzene ring and a pyrimidine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassNaphthyridines
Sub ClassQuinazolines
Direct ParentQuinazolines
Alternative Parents
Substituents
  • Quinazoline
  • Benzenesulfonamide
  • Secondary aliphatic/aromatic amine
  • Chlorobenzene
  • Benzenoid
  • Aryl halide
  • Aryl chloride
  • Vinylogous amide
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Secondary carboxylic acid amide
  • Lactam
  • Carboxamide group
  • Azacycle
  • Secondary amine
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationUsed to treat hypertension.
PharmacodynamicsQuinethazone is a thiazide diuretic used to treat hypertension. It inhibits Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue.
Mechanism of actionAs a diuretic, quinethazone inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like quinethazone also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of quinethazone is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Quinethazone Action PathwayDrug actionSMP00091
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9952
Blood Brain Barrier-0.7026
Caco-2 permeable-0.7327
P-glycoprotein substrateNon-substrate0.5421
P-glycoprotein inhibitor INon-inhibitor0.847
P-glycoprotein inhibitor IINon-inhibitor0.9619
Renal organic cation transporterNon-inhibitor0.8991
CYP450 2C9 substrateNon-substrate0.5767
CYP450 2D6 substrateNon-substrate0.8418
CYP450 3A4 substrateNon-substrate0.6226
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9011
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6867
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.7634
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.8960 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9882
hERG inhibition (predictor II)Non-inhibitor0.9334
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point251 °CPhysProp
water solubility150 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
Predicted Properties
PropertyValueSource
Water Solubility2.51 mg/mLALOGPS
logP1.6ALOGPS
logP1.19ChemAxon
logS-2.1ALOGPS
pKa (Strongest Acidic)9.56ChemAxon
pKa (Strongest Basic)-0.97ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area101.29 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity69.34 m3·mol-1ChemAxon
Polarizability27.3 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesC03BA02C03BB02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
4-Androstenedione4-Androstenedione may increase the hypokalemic activities of Quinethazone.
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Quinethazone.
AceclofenacThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Aceclofenac.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Quinethazone.
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Quinethazone is combined with Acetyldigitoxin.
Acetylsalicylic acidThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Acetylsalicylic acid.
AclidiniumThe serum concentration of Quinethazone can be increased when it is combined with Aclidinium.
AdapaleneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Adapalene.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Quinethazone.
AlclometasoneAlclometasone may increase the hypokalemic activities of Quinethazone.
AldosteroneAldosterone may increase the hypokalemic activities of Quinethazone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Quinethazone.
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Quinethazone.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Quinethazone.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Quinethazone.
AmcinonideAmcinonide may increase the hypokalemic activities of Quinethazone.
AmobarbitalAmobarbital may increase the orthostatic hypotensive activities of Quinethazone.
AmoxapineAmoxapine may increase the hyponatremic activities of Quinethazone.
Anisotropine MethylbromideThe serum concentration of Quinethazone can be increased when it is combined with Anisotropine Methylbromide.
AntipyrineThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Antipyrine.
ApremilastThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Apremilast.
ArbutamineArbutamine may increase the hypokalemic activities of Quinethazone.
ArformoterolArformoterol may increase the hypokalemic activities of Quinethazone.
Atracurium besylateThe serum concentration of Quinethazone can be increased when it is combined with Atracurium besylate.
AtropineThe serum concentration of Quinethazone can be increased when it is combined with Atropine.
AzapropazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Azapropazone.
AzelastineThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Azelastine.
BalsalazideThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Balsalazide.
BambuterolBambuterol may increase the hypokalemic activities of Quinethazone.
BarbitalBarbital may increase the orthostatic hypotensive activities of Quinethazone.
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Quinethazone.
BenactyzineThe serum concentration of Quinethazone can be increased when it is combined with Benactyzine.
BenazeprilQuinethazone may increase the hypotensive activities of Benazepril.
BenoxaprofenThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Benoxaprofen.
BenzatropineThe serum concentration of Quinethazone can be increased when it is combined with Benzatropine.
BetamethasoneBetamethasone may increase the hypokalemic activities of Quinethazone.
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Quinethazone.
BiperidenThe serum concentration of Quinethazone can be increased when it is combined with Biperiden.
BromfenacThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Bromfenac.
BudesonideBudesonide may increase the hypokalemic activities of Quinethazone.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Quinethazone.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Quinethazone.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Quinethazone.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Quinethazone.
CandoxatrilQuinethazone may increase the hypotensive activities of Candoxatril.
CaptoprilQuinethazone may increase the hypotensive activities of Captopril.
CarbamazepineThe risk or severity of adverse effects can be increased when Quinethazone is combined with Carbamazepine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Quinethazone.
CarprofenThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Carprofen.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Quinethazone.
CelecoxibThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Celecoxib.
CeliprololCeliprolol may increase the hypokalemic activities of Quinethazone.
ChloroquineThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Chloroquine.
ChlorphenoxamineThe serum concentration of Quinethazone can be increased when it is combined with Chlorphenoxamine.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Quinethazone.
CholestyramineCholestyramine can cause a decrease in the absorption of Quinethazone resulting in a reduced serum concentration and potentially a decrease in efficacy.
CiclesonideCiclesonide may increase the hypokalemic activities of Quinethazone.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Quinethazone.
CilazaprilQuinethazone may increase the hypotensive activities of Cilazapril.
CitalopramCitalopram may increase the hyponatremic activities of Quinethazone.
ClenbuterolClenbuterol may increase the hypokalemic activities of Quinethazone.
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Quinethazone.
ClocortoloneClocortolone may increase the hypokalemic activities of Quinethazone.
ClomipramineClomipramine may increase the hyponatremic activities of Quinethazone.
ClonixinThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Clonixin.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Quinethazone.
ColesevelamColesevelam can cause a decrease in the absorption of Quinethazone resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Quinethazone resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Quinethazone.
CyclopentolateThe serum concentration of Quinethazone can be increased when it is combined with Cyclopentolate.
CyclophosphamideThe risk or severity of adverse effects can be increased when Quinethazone is combined with Cyclophosphamide.
D-LimoneneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with D-Limonene.
DapoxetineDapoxetine may increase the hyponatremic activities of Quinethazone.
DarifenacinThe serum concentration of Quinethazone can be increased when it is combined with Darifenacin.
DehydroepiandrosteroneDehydroepiandrosterone may increase the hypokalemic activities of Quinethazone.
dehydroepiandrosterone sulfatedehydroepiandrosterone sulfate may increase the hypokalemic activities of Quinethazone.
DeslanosideThe risk or severity of adverse effects can be increased when Quinethazone is combined with Deslanoside.
DesloratadineThe serum concentration of Quinethazone can be increased when it is combined with Desloratadine.
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Quinethazone.
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Quinethazone.
DexamethasoneDexamethasone may increase the hypokalemic activities of Quinethazone.
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Quinethazone.
DexetimideThe serum concentration of Quinethazone can be increased when it is combined with Dexetimide.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Quinethazone.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Quinethazone.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Quinethazone.
DiazoxideThe risk or severity of adverse effects can be increased when Quinethazone is combined with Diazoxide.
DiclofenacThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Diclofenac.
DicyclomineThe serum concentration of Quinethazone can be increased when it is combined with Dicyclomine.
DiflorasoneDiflorasone may increase the hypokalemic activities of Quinethazone.
DiflunisalThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Diflunisal.
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Quinethazone.
DifluprednateDifluprednate may increase the hypokalemic activities of Quinethazone.
DigitoxinThe risk or severity of adverse effects can be increased when Quinethazone is combined with Digitoxin.
DigoxinThe risk or severity of adverse effects can be increased when Quinethazone is combined with Digoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Quinethazone.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Quinethazone.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Quinethazone.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Quinethazone.
DipivefrinDipivefrin may increase the hypokalemic activities of Quinethazone.
DobutamineDobutamine may increase the hypokalemic activities of Quinethazone.
DofetilideQuinethazone may increase the QTc-prolonging activities of Dofetilide.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Quinethazone.
DroxicamThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Droxicam.
DroxidopaDroxidopa may increase the hypokalemic activities of Quinethazone.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Quinethazone.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Quinethazone.
EnalaprilQuinethazone may increase the hypotensive activities of Enalapril.
EnalaprilatQuinethazone may increase the hypotensive activities of Enalaprilat.
EphedraEphedra may increase the hypokalemic activities of Quinethazone.
EpinephrineEpinephrine may increase the hypokalemic activities of Quinethazone.
EpirizoleThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Epirizole.
EquileninEquilenin may increase the hypokalemic activities of Quinethazone.
EquilinEquilin may increase the hypokalemic activities of Quinethazone.
EscitalopramEscitalopram may increase the hyponatremic activities of Quinethazone.
EstroneEstrone may increase the hypokalemic activities of Quinethazone.
EtanerceptThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Etanercept.
EthanolEthanol may increase the orthostatic hypotensive activities of Quinethazone.
EthopropazineThe serum concentration of Quinethazone can be increased when it is combined with Ethopropazine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Quinethazone.
EtodolacThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Etodolac.
EtofenamateThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Etofenamate.
EtoperidoneEtoperidone may increase the hyponatremic activities of Quinethazone.
EtoricoxibThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Etoricoxib.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Quinethazone.
Evening primrose oilThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Evening primrose oil.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Quinethazone.
exisulindThe therapeutic efficacy of Quinethazone can be decreased when used in combination with exisulind.
FenbufenThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Fenbufen.
FenfluramineFenfluramine may increase the hyponatremic activities of Quinethazone.
FenoprofenThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Fenoprofen.
FenoterolFenoterol may increase the hypokalemic activities of Quinethazone.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Quinethazone.
FesoterodineThe serum concentration of Quinethazone can be increased when it is combined with Fesoterodine.
FloctafenineThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Floctafenine.
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Quinethazone.
FlumethasoneFlumethasone may increase the hypokalemic activities of Quinethazone.
FlunisolideFlunisolide may increase the hypokalemic activities of Quinethazone.
FlunixinThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Flunixin.
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Quinethazone.
FluocinonideFluocinonide may increase the hypokalemic activities of Quinethazone.
FluocortoloneFluocortolone may increase the hypokalemic activities of Quinethazone.
FluorometholoneFluorometholone may increase the hypokalemic activities of Quinethazone.
FluoxetineFluoxetine may increase the hyponatremic activities of Quinethazone.
FluprednideneFluprednidene may increase the hypokalemic activities of Quinethazone.
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Quinethazone.
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Quinethazone.
FlurbiprofenThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Flurbiprofen.
Fluticasone furoateFluticasone furoate may increase the hypokalemic activities of Quinethazone.
Fluticasone PropionateFluticasone Propionate may increase the hypokalemic activities of Quinethazone.
FluvoxamineFluvoxamine may increase the hyponatremic activities of Quinethazone.
FormoterolFormoterol may increase the hypokalemic activities of Quinethazone.
FosinoprilQuinethazone may increase the hypotensive activities of Fosinopril.
Gallamine TriethiodideThe serum concentration of Quinethazone can be increased when it is combined with Gallamine Triethiodide.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Quinethazone.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Quinethazone.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Quinethazone.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Quinethazone.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Quinethazone.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Quinethazone.
GlycopyrroniumThe serum concentration of Quinethazone can be increased when it is combined with Glycopyrronium.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Quinethazone.
HexamethoniumThe serum concentration of Quinethazone can be increased when it is combined with Hexamethonium.
HexobarbitalHexobarbital may increase the orthostatic hypotensive activities of Quinethazone.
HMPL-004The therapeutic efficacy of Quinethazone can be decreased when used in combination with HMPL-004.
HomatropineThe serum concentration of Quinethazone can be increased when it is combined with Homatropine.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Quinethazone.
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Quinethazone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Quinethazone.
HyoscyamineThe serum concentration of Quinethazone can be increased when it is combined with Hyoscyamine.
IbuprofenThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Ibuprofen.
IbuproxamThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Ibuproxam.
IcatibantThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Icatibant.
IndacaterolIndacaterol may increase the hypokalemic activities of Quinethazone.
IndalpineIndalpine may increase the hyponatremic activities of Quinethazone.
IndomethacinThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Indomethacin.
IndoprofenThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Indoprofen.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Quinethazone.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Quinethazone.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Quinethazone.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Quinethazone.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Quinethazone.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Quinethazone.
Ipratropium bromideThe serum concentration of Quinethazone can be increased when it is combined with Ipratropium bromide.
IsoetarineIsoetarine may increase the hypokalemic activities of Quinethazone.
IsoprenalineIsoprenaline may increase the hypokalemic activities of Quinethazone.
IsoxicamThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Isoxicam.
IvabradineQuinethazone may increase the arrhythmogenic activities of Ivabradine.
KebuzoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Kebuzone.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Quinethazone.
KetoprofenThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Ketoprofen.
KetorolacThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Ketorolac.
LeflunomideThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Leflunomide.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Quinethazone.
LevomilnacipranLevomilnacipran may increase the hyponatremic activities of Quinethazone.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Quinethazone.
LicoriceLicorice may increase the hypokalemic activities of Quinethazone.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Quinethazone.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Quinethazone.
LisinoprilQuinethazone may increase the hypotensive activities of Lisinopril.
LithiumQuinethazone may decrease the excretion rate of Lithium which could result in a lower serum level and potentially a reduction in efficacy.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Quinethazone.
LornoxicamThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Lornoxicam.
LoxoprofenThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Loxoprofen.
Lu AA21004Lu AA21004 may increase the hyponatremic activities of Quinethazone.
LumiracoxibThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Lumiracoxib.
Magnesium salicylateThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Magnesium salicylate.
MasoprocolThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Masoprocol.
MecamylamineThe serum concentration of Quinethazone can be increased when it is combined with Mecamylamine.
Meclofenamic acidThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Meclofenamic acid.
MedrysoneMedrysone may increase the hypokalemic activities of Quinethazone.
Mefenamic acidThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Mefenamic acid.
MelengestrolMelengestrol may increase the hypokalemic activities of Quinethazone.
MeloxicamThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Meloxicam.
MesalazineThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Mesalazine.
MetamizoleThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Metamizole.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Quinethazone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Quinethazone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Quinethazone.
MethanthelineThe serum concentration of Quinethazone can be increased when it is combined with Methantheline.
MethohexitalMethohexital may increase the orthostatic hypotensive activities of Quinethazone.
MethylphenobarbitalMethylphenobarbital may increase the orthostatic hypotensive activities of Quinethazone.
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Quinethazone.
MetixeneThe serum concentration of Quinethazone can be increased when it is combined with Metixene.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Quinethazone.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Quinethazone.
MilnacipranMilnacipran may increase the hyponatremic activities of Quinethazone.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Quinethazone.
MoexiprilQuinethazone may increase the hypotensive activities of Moexipril.
MometasoneMometasone may increase the hypokalemic activities of Quinethazone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Quinethazone.
Mycophenolate mofetilThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Mycophenolate mofetil.
Mycophenolic acidThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Mycophenolic acid.
N-butylscopolammonium bromideThe serum concentration of Quinethazone can be increased when it is combined with N-butylscopolammonium bromide.
NabumetoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Nabumetone.
NaftifineThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Naftifine.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Quinethazone.
NaproxenThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Naproxen.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Quinethazone.
NCX 4016The therapeutic efficacy of Quinethazone can be decreased when used in combination with NCX 4016.
NepafenacThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Nepafenac.
Niflumic AcidThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Niflumic Acid.
NimesulideThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Nimesulide.
NorepinephrineNorepinephrine may increase the hypokalemic activities of Quinethazone.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Quinethazone.
NVA237The serum concentration of Quinethazone can be increased when it is combined with NVA237.
OlanzapineOlanzapine may increase the hyponatremic activities of Quinethazone.
OlodaterolOlodaterol may increase the hypokalemic activities of Quinethazone.
OlopatadineThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Olopatadine.
OlsalazineThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Olsalazine.
OmapatrilatQuinethazone may increase the hypotensive activities of Omapatrilat.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Quinethazone.
OrciprenalineOrciprenaline may increase the hypokalemic activities of Quinethazone.
OrgoteinThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Orgotein.
OrphenadrineThe serum concentration of Quinethazone can be increased when it is combined with Orphenadrine.
OuabainThe risk or severity of adverse effects can be increased when Quinethazone is combined with Ouabain.
OxaprozinThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Oxaprozin.
OxcarbazepineThe risk or severity of adverse effects can be increased when Quinethazone is combined with Oxcarbazepine.
OxybutyninThe serum concentration of Quinethazone can be increased when it is combined with Oxybutynin.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Quinethazone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Quinethazone.
OxyphenbutazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Oxyphenbutazone.
OxyphenoniumThe serum concentration of Quinethazone can be increased when it is combined with Oxyphenonium.
PancuroniumThe serum concentration of Quinethazone can be increased when it is combined with Pancuronium.
ParamethasoneParamethasone may increase the hypokalemic activities of Quinethazone.
ParecoxibThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Parecoxib.
ParoxetineParoxetine may increase the hyponatremic activities of Quinethazone.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Quinethazone.
PentobarbitalPentobarbital may increase the orthostatic hypotensive activities of Quinethazone.
PentoliniumThe serum concentration of Quinethazone can be increased when it is combined with Pentolinium.
PerindoprilQuinethazone may increase the hypotensive activities of Perindopril.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Quinethazone.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Quinethazone.
PhenobarbitalPhenobarbital may increase the orthostatic hypotensive activities of Quinethazone.
PhenylbutazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Phenylbutazone.
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Quinethazone.
PimecrolimusThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Pimecrolimus.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Quinethazone.
PipecuroniumThe serum concentration of Quinethazone can be increased when it is combined with Pipecuronium.
PirbuterolPirbuterol may increase the hypokalemic activities of Quinethazone.
PirenzepineThe serum concentration of Quinethazone can be increased when it is combined with Pirenzepine.
PirfenidoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Pirfenidone.
PiroxicamThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Piroxicam.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Quinethazone.
PrednicarbatePrednicarbate may increase the hypokalemic activities of Quinethazone.
PrednisolonePrednisolone may increase the hypokalemic activities of Quinethazone.
PrednisonePrednisone may increase the hypokalemic activities of Quinethazone.
PregnenolonePregnenolone may increase the hypokalemic activities of Quinethazone.
PrimidonePrimidone may increase the orthostatic hypotensive activities of Quinethazone.
ProcaterolProcaterol may increase the hypokalemic activities of Quinethazone.
ProcyclidineThe serum concentration of Quinethazone can be increased when it is combined with Procyclidine.
PropacetamolThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Propacetamol.
PropanthelineThe serum concentration of Quinethazone can be increased when it is combined with Propantheline.
PTC299The therapeutic efficacy of Quinethazone can be decreased when used in combination with PTC299.
QuinaprilQuinethazone may increase the hypotensive activities of Quinapril.
QuinidineThe serum concentration of Quinethazone can be increased when it is combined with Quinidine.
RamiprilQuinethazone may increase the hypotensive activities of Ramipril.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Quinethazone.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Quinethazone.
RescinnamineQuinethazone may increase the hypotensive activities of Rescinnamine.
ResveratrolThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Resveratrol.
RimexoloneRimexolone may increase the hypokalemic activities of Quinethazone.
RitodrineRitodrine may increase the hypokalemic activities of Quinethazone.
RofecoxibThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Rofecoxib.
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Quinethazone.
SalbutamolSalbutamol may increase the hypokalemic activities of Quinethazone.
SalicylamideThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Salicylamide.
Salicylic acidThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Salicylic acid.
SalmeterolSalmeterol may increase the hypokalemic activities of Quinethazone.
SalsalateThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Salsalate.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Quinethazone.
ScopolamineThe serum concentration of Quinethazone can be increased when it is combined with Scopolamine.
Scopolamine butylbromideThe serum concentration of Quinethazone can be increased when it is combined with Scopolamine butylbromide.
SecobarbitalSecobarbital may increase the orthostatic hypotensive activities of Quinethazone.
SeratrodastThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Seratrodast.
SertralineSertraline may increase the hyponatremic activities of Quinethazone.
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Quinethazone.
SolifenacinThe serum concentration of Quinethazone can be increased when it is combined with Solifenacin.
SpiraprilQuinethazone may increase the hypotensive activities of Spirapril.
SRT501The therapeutic efficacy of Quinethazone can be decreased when used in combination with SRT501.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Quinethazone.
SulfasalazineThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Sulfasalazine.
SulindacThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Sulindac.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Quinethazone.
SulpirideThe risk or severity of adverse effects can be increased when Quinethazone is combined with Sulpiride.
SuprofenThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Suprofen.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Quinethazone.
TemocaprilQuinethazone may increase the hypotensive activities of Temocapril.
TenoxicamThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Tenoxicam.
TepoxalinThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Tepoxalin.
TerbutalineTerbutaline may increase the hypokalemic activities of Quinethazone.
TeriflunomideThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Teriflunomide.
ThiamylalThiamylal may increase the orthostatic hypotensive activities of Quinethazone.
ThiopentalThiopental may increase the orthostatic hypotensive activities of Quinethazone.
Tiaprofenic acidThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Tiaprofenic acid.
TiotropiumThe serum concentration of Quinethazone can be increased when it is combined with Tiotropium.
TixocortolTixocortol may increase the hypokalemic activities of Quinethazone.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Quinethazone.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Quinethazone.
Tolfenamic AcidThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Tolfenamic Acid.
TolmetinThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Tolmetin.
TolterodineThe serum concentration of Quinethazone can be increased when it is combined with Tolterodine.
TopiramateQuinethazone may increase the hypokalemic activities of Topiramate.
ToremifeneQuinethazone may increase the hypercalcemic activities of Toremifene.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Quinethazone.
TrandolaprilQuinethazone may increase the hypotensive activities of Trandolapril.
TranilastThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Tranilast.
TrazodoneTrazodone may increase the hyponatremic activities of Quinethazone.
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Quinethazone.
TrihexyphenidylThe serum concentration of Quinethazone can be increased when it is combined with Trihexyphenidyl.
TrimethaphanThe serum concentration of Quinethazone can be increased when it is combined with Trimethaphan.
Trisalicylate-cholineThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Trisalicylate-choline.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Quinethazone.
TropicamideThe serum concentration of Quinethazone can be increased when it is combined with Tropicamide.
TrospiumThe serum concentration of Quinethazone can be increased when it is combined with Trospium.
TubocurarineThe serum concentration of Quinethazone can be increased when it is combined with Tubocurarine.
UmeclidiniumThe serum concentration of Quinethazone can be increased when it is combined with Umeclidinium.
ValdecoxibThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Valdecoxib.
VecuroniumThe serum concentration of Quinethazone can be increased when it is combined with Vecuronium.
VilanterolVilanterol may increase the hypokalemic activities of Quinethazone.
VilazodoneVilazodone may increase the hyponatremic activities of Quinethazone.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Quinethazone.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Quinethazone.
VortioxetineVortioxetine may increase the hyponatremic activities of Quinethazone.
ZaltoprofenThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Zaltoprofen.
ZileutonThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Zileuton.
ZimelidineZimelidine may increase the hyponatremic activities of Quinethazone.
ZomepiracThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Zomepirac.
Food Interactions
  • Take with food to increase bioavailability.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Reversible hydration of carbon dioxide. Can hydrates cyanamide to urea.
Gene Name:
CA1
Uniprot ID:
P00915
Molecular Weight:
28870.0 Da
References
  1. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Sulfonamide diuretics revisited--old leads for new applications? Org Biomol Chem. 2008 Jul 21;6(14):2499-506. doi: 10.1039/b800767e. Epub 2008 May 29. [PubMed:18600270 ]
  2. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct. Bioorg Med Chem Lett. 2008 Apr 15;18(8):2567-73. doi: 10.1016/j.bmcl.2008.03.051. Epub 2008 Mar 20. [PubMed:18374572 ]
  3. Supuran CT: Diuretics: from classical carbonic anhydrase inhibitors to novel applications of the sulfonamides. Curr Pharm Des. 2008;14(7):641-8. [PubMed:18336309 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion into the anterior chamber of the eye. Contributes to intracellular pH regulation in the duodenal upper villous epithelium during proton-coupled peptide absorption. Stimulates the chloride-bicarbonate ex...
Gene Name:
CA2
Uniprot ID:
P00918
Molecular Weight:
29245.895 Da
References
  1. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Sulfonamide diuretics revisited--old leads for new applications? Org Biomol Chem. 2008 Jul 21;6(14):2499-506. doi: 10.1039/b800767e. Epub 2008 May 29. [PubMed:18600270 ]
  2. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct. Bioorg Med Chem Lett. 2008 Apr 15;18(8):2567-73. doi: 10.1016/j.bmcl.2008.03.051. Epub 2008 Mar 20. [PubMed:18374572 ]
  3. Supuran CT: Diuretics: from classical carbonic anhydrase inhibitors to novel applications of the sulfonamides. Curr Pharm Des. 2008;14(7):641-8. [PubMed:18336309 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Sodium:potassium:chloride symporter activity
Specific Function:
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name:
SLC12A1
Uniprot ID:
Q13621
Molecular Weight:
121449.13 Da
References
  1. Duarte JD, Cooper-DeHoff RM: Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics. Expert Rev Cardiovasc Ther. 2010 Jun;8(6):793-802. doi: 10.1586/erc.10.27. [PubMed:20528637 ]
  2. Gamba G: The thiazide-sensitive Na+-Cl- cotransporter: molecular biology, functional properties, and regulation by WNKs. Am J Physiol Renal Physiol. 2009 Oct;297(4):F838-48. doi: 10.1152/ajprenal.00159.2009. Epub 2009 May 27. [PubMed:19474192 ]
  3. Ellison DH: The thiazide-sensitive na-cl cotransporter and human disease: reemergence of an old player. J Am Soc Nephrol. 2003 Feb;14(2):538-40. [PubMed:12538756 ]
  4. Ko B, Hoover RS: Molecular physiology of the thiazide-sensitive sodium-chloride cotransporter. Curr Opin Nephrol Hypertens. 2009 Sep;18(5):421-7. doi: 10.1097/MNH.0b013e32832f2fcb. [PubMed:19636250 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Sodium:potassium:chloride symporter activity
Specific Function:
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name:
SLC12A2
Uniprot ID:
P55011
Molecular Weight:
131445.825 Da
References
  1. Duarte JD, Cooper-DeHoff RM: Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics. Expert Rev Cardiovasc Ther. 2010 Jun;8(6):793-802. doi: 10.1586/erc.10.27. [PubMed:20528637 ]
  2. Gamba G: The thiazide-sensitive Na+-Cl- cotransporter: molecular biology, functional properties, and regulation by WNKs. Am J Physiol Renal Physiol. 2009 Oct;297(4):F838-48. doi: 10.1152/ajprenal.00159.2009. Epub 2009 May 27. [PubMed:19474192 ]
  3. Ellison DH: The thiazide-sensitive na-cl cotransporter and human disease: reemergence of an old player. J Am Soc Nephrol. 2003 Feb;14(2):538-40. [PubMed:12538756 ]
  4. Ko B, Hoover RS: Molecular physiology of the thiazide-sensitive sodium-chloride cotransporter. Curr Opin Nephrol Hypertens. 2009 Sep;18(5):421-7. doi: 10.1097/MNH.0b013e32832f2fcb. [PubMed:19636250 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Key mediator of sodium and chloride reabsorption in this nephron segment, accounting for a significant fraction of renal sodium reabsorption.
Gene Name:
SLC12A3
Uniprot ID:
P55017
Molecular Weight:
113138.04 Da
References
  1. Duarte JD, Cooper-DeHoff RM: Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics. Expert Rev Cardiovasc Ther. 2010 Jun;8(6):793-802. doi: 10.1586/erc.10.27. [PubMed:20528637 ]
  2. Gamba G: The thiazide-sensitive Na+-Cl- cotransporter: molecular biology, functional properties, and regulation by WNKs. Am J Physiol Renal Physiol. 2009 Oct;297(4):F838-48. doi: 10.1152/ajprenal.00159.2009. Epub 2009 May 27. [PubMed:19474192 ]
  3. Ellison DH: The thiazide-sensitive na-cl cotransporter and human disease: reemergence of an old player. J Am Soc Nephrol. 2003 Feb;14(2):538-40. [PubMed:12538756 ]
  4. Ko B, Hoover RS: Molecular physiology of the thiazide-sensitive sodium-chloride cotransporter. Curr Opin Nephrol Hypertens. 2009 Sep;18(5):421-7. doi: 10.1097/MNH.0b013e32832f2fcb. [PubMed:19636250 ]
Comments
comments powered by Disqus
Drug created on June 30, 2007 11:21 / Updated on August 17, 2016 12:23